Active 0 6 0 6 O
Hepatitis 7 16 7 16 B-chronic_disease
B 17 18 17 18 I-chronic_disease
( 19 20 19 20 O
HBsAg 20 25 20 25 O
reactive 26 34 26 34 O

Active 0 6 35 41 O
Hepatitis 7 16 42 51 B-chronic_disease
C 17 18 52 53 I-chronic_disease
( 19 20 54 55 O
HCV 20 23 55 58 B-chronic_disease
- 23 24 58 59 O
RNA 24 27 59 62 O
qualitative 28 39 63 74 O
) 39 40 74 75 O

Currently 0 9 76 85 O
breast 10 16 86 92 O
feeding 17 24 93 100 O
, 24 25 100 101 O
pregnant 26 34 102 110 B-pregnancy
or 35 37 111 113 O
planning 38 46 114 122 B-pregnancy
to 47 49 123 125 I-pregnancy
conceive 50 58 126 134 I-pregnancy
or 59 61 135 137 O
father 62 68 138 144 O
Children 69 77 145 153 O
from 78 82 154 158 O
screening 83 92 159 168 O
through 93 100 169 176 O
120 101 104 177 180 B-upper_bound
Days 105 109 181 185 I-upper_bound
after 110 115 186 191 I-upper_bound
last 116 120 192 196 O
dose 121 125 197 201 O
of 126 128 202 204 O
study 129 134 205 210 B-treatment
drug 135 139 211 215 I-treatment

Eastern 0 7 216 223 B-clinical_variable
Cooperative 8 19 224 235 I-clinical_variable
Oncology 20 28 236 244 I-clinical_variable
Group 29 34 245 250 I-clinical_variable
( 35 36 251 252 I-clinical_variable
ECOG 36 40 252 256 I-clinical_variable
) 40 41 256 257 I-clinical_variable
score 42 47 258 263 I-clinical_variable
of 48 50 264 266 O
0 51 52 267 268 B-lower_bound
or 53 55 269 271 O
1 56 57 272 273 B-upper_bound

Evidence 0 8 274 282 O
of 9 11 283 285 O
active 12 18 286 292 O
, 18 19 292 293 O
non 20 23 294 297 O
- 23 24 297 298 O
infectious 24 34 298 308 O
pneumonitis 35 46 309 320 B-chronic_disease
or 47 49 321 323 O
a 50 51 324 325 O
history 52 59 326 333 O
of 60 62 334 336 O
interstitial 63 75 337 349 B-chronic_disease
lung 76 80 350 354 I-chronic_disease
disease 81 88 355 362 I-chronic_disease

Histologically 0 14 363 377 O
confirmed 15 24 378 387 O
solid 25 30 388 393 O
malignancy 31 41 394 404 B-cancer
that 42 46 405 409 O
is 47 49 410 412 O
metastatic 50 60 413 423 O
or 61 63 424 426 O
unresectable 64 76 427 439 O
for 77 80 440 443 O
which 81 86 444 449 O
standard 87 95 450 458 O
curative 96 104 459 467 O
or 105 107 468 470 O
palliative 108 118 471 481 O
measures 119 127 482 490 O
do 128 130 491 493 O
not 131 134 494 497 O
exist 135 140 498 503 O
or 141 143 504 506 O
are 144 147 507 510 O
no 148 150 511 513 O
longer 151 157 514 520 O
effective 158 167 521 530 O
( 168 169 531 532 O
Dose 169 173 532 536 O
Escalation 174 184 537 547 O
phase 185 190 548 553 O
only 191 195 554 558 O
) 195 196 558 559 O

History 0 7 560 567 O
of 8 10 568 570 O
allergic 11 19 571 579 O
reactions 20 29 580 589 O
attributed 30 40 590 600 O
to 41 43 601 603 O
compounds 44 53 604 613 O
of 54 56 614 616 O
similar 57 64 617 624 O
chemical 65 73 625 633 O
or 74 76 634 636 O
biologic 77 85 637 645 O
composition 86 97 646 657 O
to 98 100 658 660 O
birinapant 101 111 661 671 B-allergy_name
or 112 114 672 674 O
pembrolizumab 115 128 675 688 B-allergy_name
or 129 131 689 691 O
their 132 137 692 697 O
constituents 138 150 698 710 O

Known 0 5 711 716 O
history 6 13 717 724 O
of 14 16 725 727 O
Human 17 22 728 733 B-chronic_disease
Immunodeficiency 23 39 734 750 I-chronic_disease
Virus 40 45 751 756 I-chronic_disease
( 46 47 757 758 I-chronic_disease
HIV 47 50 758 761 I-chronic_disease
( 51 52 762 763 O
HIV1/2 52 58 763 769 O
antibodies 59 69 770 780 O
) 69 70 780 781 O

Patients 0 8 782 790 O
must 9 13 791 795 O
have 14 18 796 800 O
a 19 20 801 802 O
histologically 21 35 803 817 O
confirmed 36 45 818 827 O
epithelial 46 56 828 838 B-cancer
ovarian 57 64 839 846 I-cancer
cancer 65 71 847 853 I-cancer
, 71 72 853 854 O
primary 73 80 855 862 B-cancer
peritoneal 81 91 863 873 I-cancer
cancer 92 98 874 880 I-cancer
or 99 101 881 883 O
fallopian 102 111 884 893 B-cancer
tube 112 116 894 898 I-cancer
solid 117 122 899 904 I-cancer
tumor 123 128 905 910 I-cancer
cancer 129 135 911 917 I-cancer
that 136 140 918 922 O
is 141 143 923 925 O
locally 144 151 926 933 O
advanced 152 160 934 942 O
or 161 163 943 945 O
metastatic 164 174 946 956 B-cancer
with 175 179 957 961 O
no 180 182 962 964 O
available 183 192 965 974 O
therapy 193 200 975 982 B-treatment
options 201 208 983 990 O
that 209 213 991 995 O
are 214 217 996 999 O
known 218 223 1000 1005 O
to 224 226 1006 1008 O
provide 227 234 1009 1016 O
clinical 235 243 1017 1025 O
benefit 244 251 1026 1033 O
per 252 255 1034 1037 O
institutional 256 269 1038 1051 O
standard 270 278 1052 1060 O
of 279 281 1061 1063 O
care 282 286 1064 1068 O

Patients 0 8 1069 1077 O
must 9 13 1078 1082 O
have 14 18 1083 1087 O
a 19 20 1088 1089 O
histologically 21 35 1090 1104 O
confirmed 36 45 1105 1114 O
epithelial 46 56 1115 1125 B-cancer
ovarian 57 64 1126 1133 I-cancer
cancer 65 71 1134 1140 I-cancer
, 71 72 1140 1141 O
primary 73 80 1142 1149 B-cancer
peritoneal 81 91 1150 1160 I-cancer
cancer 92 98 1161 1167 I-cancer
or 99 101 1168 1170 O
fallopian 102 111 1171 1180 B-cancer
tube 112 116 1181 1185 I-cancer
solid 117 122 1186 1191 I-cancer
tumor 123 128 1192 1197 I-cancer
cancer 129 135 1198 1204 I-cancer
that 136 140 1205 1209 O
is 141 143 1210 1212 O
locally 144 151 1213 1220 O
advanced 152 160 1221 1229 O
or 161 163 1230 1232 O
metastatic 164 174 1233 1243 O
with 175 179 1244 1248 O
no 180 182 1249 1251 O
available 183 192 1252 1261 O
therapy 193 200 1262 1269 B-treatment
options 201 208 1270 1277 O
that 209 213 1278 1282 O
are 214 217 1283 1286 O
known 218 223 1287 1292 O
to 224 226 1293 1295 O
provide 227 234 1296 1303 O
clinical 235 243 1304 1312 O
benefit 244 251 1313 1320 O
per 252 255 1321 1324 O
institutional 256 269 1325 1338 O
standard 270 278 1339 1347 O
of 279 281 1348 1350 O
care 282 286 1351 1355 O
. 286 287 1355 1356 O
( 288 289 1357 1358 O
ovarian 289 296 1358 1365 O
cancer 297 303 1366 1372 O
cohort 304 310 1373 1379 O
only 311 315 1380 1384 O
) 315 316 1384 1385 O

Patients 0 8 1386 1394 O
must 9 13 1395 1399 O
have 14 18 1400 1404 O
experienced 19 30 1405 1416 O
documented 31 41 1417 1427 O
, 41 42 1427 1428 O
confirmed 43 52 1429 1438 O
radiographic 53 65 1439 1451 O
progression 66 77 1452 1463 O
of 78 80 1464 1466 O
disease 81 88 1467 1474 O
by 89 91 1475 1477 O
iRECIST 92 99 1478 1485 O
, 99 100 1485 1486 O
or 101 103 1487 1489 O
by 104 106 1490 1492 O
RECIST 107 113 1493 1499 O
v1.1 114 118 1500 1504 O
( 119 120 1505 1506 O
various 120 127 1506 1513 O
solid 128 133 1514 1519 B-cancer
tumors 134 140 1520 1526 I-cancer
cohort 141 147 1527 1533 O
head 148 152 1534 1538 B-cancer
and 153 156 1539 1542 I-cancer
neck 157 161 1543 1547 I-cancer
squamous 162 170 1548 1556 I-cancer
cell 171 175 1557 1561 I-cancer
carcinoma 176 185 1562 1571 I-cancer
, 185 186 1571 1572 O
Check 187 192 1573 1578 O
point 193 198 1579 1584 O
inhibitor 199 208 1585 1594 O
experienced 209 220 1595 1606 O
group 221 226 1607 1612 O
only 227 231 1613 1617 O
) 231 232 1617 1618 O

Patients 0 8 1619 1627 O
must 9 13 1628 1632 O
have 14 18 1633 1637 O
histologically 19 33 1638 1652 O
or 34 36 1653 1655 O
cytologically 37 50 1656 1669 O
confirmed 51 60 1670 1679 O
carcinoma 61 70 1680 1689 B-cancer
of 71 73 1690 1692 I-cancer
the 74 77 1693 1696 I-cancer
esophagus 78 87 1697 1706 I-cancer
including 88 97 1707 1716 O
the 98 101 1717 1720 O
gastroesophageal 102 118 1721 1737 O
junction 119 127 1738 1746 O
that 128 132 1747 1751 O
is 133 135 1752 1754 O
locally 136 143 1755 1762 O
advanced 144 152 1763 1771 B-cancer
or 153 155 1772 1774 O
metastatic 156 166 1775 1785 B-cancer
with 167 171 1786 1790 O
no 172 174 1791 1793 O
available 175 184 1794 1803 O
therapy 185 192 1804 1811 B-treatment
options 193 200 1812 1819 O
that 201 205 1820 1824 O
are 206 209 1825 1828 O
known 210 215 1829 1834 O
to 216 218 1835 1837 O
provide 219 226 1838 1845 O
clinical 227 235 1846 1854 O
benefit 236 243 1855 1862 O
per 244 247 1863 1866 O
institutional 248 261 1867 1880 O
standard 262 270 1881 1889 O
of 271 273 1890 1892 O
care 274 278 1893 1897 O
. 278 279 1897 1898 O
( 280 281 1899 1900 O
various 281 288 1900 1907 O
solid 289 294 1908 1913 B-cancer
tumors 295 301 1914 1920 I-cancer
cohort 302 308 1921 1927 O
, 308 309 1927 1928 O
gastroesophageal 310 326 1929 1945 B-cancer
carcinoma 327 336 1946 1955 I-cancer
group 337 342 1956 1961 O
only 343 347 1962 1966 O
) 347 348 1966 1967 O

Patients 0 8 1968 1976 O
must 9 13 1977 1981 O
have 14 18 1982 1986 O
histologically 19 33 1987 2001 O
or 34 36 2002 2004 O
cytologically 37 50 2005 2018 O
confirmed 51 60 2019 2028 O
cervical 61 69 2029 2037 B-cancer
squamous 70 78 2038 2046 I-cancer
cell 79 83 2047 2051 I-cancer
carcinoma 84 93 2052 2061 I-cancer
that 94 98 2062 2066 O
is 99 101 2067 2069 O
locally 102 109 2070 2077 O
advanced 110 118 2078 2086 O
or 119 121 2087 2089 O
metastatic 122 132 2090 2100 B-cancer
with 133 137 2101 2105 O
no 138 140 2106 2108 O
available 141 150 2109 2118 O
therapy 151 158 2119 2126 B-treatment
options 159 166 2127 2134 O
that 167 171 2135 2139 O
are 172 175 2140 2143 O
known 176 181 2144 2149 O
to 182 184 2150 2152 O
provide 185 192 2153 2160 O
clinical 193 201 2161 2169 O
benefit 202 209 2170 2177 O
per 210 213 2178 2181 O
institutional 214 227 2182 2195 O
standard 228 236 2196 2204 O
of 237 239 2205 2207 O
care 240 244 2208 2212 O

Patients 0 8 2213 2221 O
must 9 13 2222 2226 O
have 14 18 2227 2231 O
histologically 19 33 2232 2246 O
or 34 36 2247 2249 O
cytologically 37 50 2250 2263 O
confirmed 51 60 2264 2273 O
cholangiocarcinoma 61 79 2274 2292 B-cancer
that 80 84 2293 2297 O
is 85 87 2298 2300 O
locally 88 95 2301 2308 O
advanced 96 104 2309 2317 O
or 105 107 2318 2320 O
metastatic 108 118 2321 2331 O
with 119 123 2332 2336 O
no 124 126 2337 2339 O
available 127 136 2340 2349 O
therapy 137 144 2350 2357 B-treatment
options 145 152 2358 2365 O
that 153 157 2366 2370 O
are 158 161 2371 2374 O
known 162 167 2375 2380 O
to 168 170 2381 2383 O
provide 171 178 2384 2391 O
clinical 179 187 2392 2400 O
benefit 188 195 2401 2408 O
per 196 199 2409 2412 O
institutional 200 213 2413 2426 O
standard 214 222 2427 2435 O
of 223 225 2436 2438 O
care 226 230 2439 2443 O
. 230 231 2443 2444 O
( 232 233 2445 2446 O
various 233 240 2446 2453 O
solid 241 246 2454 2459 B-cancer
tumors 247 253 2460 2466 I-cancer
cohort 254 260 2467 2473 O
, 260 261 2473 2474 O
cholangiocarcinoma 262 280 2475 2493 O
group 281 286 2494 2499 O
only 287 291 2500 2504 O
) 291 292 2504 2505 O

Patients 0 8 2506 2514 O
must 9 13 2515 2519 O
have 14 18 2520 2524 O
histologically 19 33 2525 2539 O
or 34 36 2540 2542 O
cytologically 37 50 2543 2556 O
confirmed 51 60 2557 2566 O
head 61 65 2567 2571 B-cancer
and 66 69 2572 2575 I-cancer
neck 70 74 2576 2580 I-cancer
squamous 75 83 2581 2589 I-cancer
cell 84 88 2590 2594 I-cancer
carcinoma 89 98 2595 2604 I-cancer
that 99 103 2605 2609 O
is 104 106 2610 2612 O
locally 107 114 2613 2620 O
advanced 115 123 2621 2629 O
or 124 126 2630 2632 O
metastatic 127 137 2633 2643 O
with 138 142 2644 2648 O
no 143 145 2649 2651 O
available 146 155 2652 2661 O
therapy 156 163 2662 2669 B-treatment
options 164 171 2670 2677 O
that 172 176 2678 2682 O
are 177 180 2683 2686 O
known 181 186 2687 2692 O
to 187 189 2693 2695 O
provide 190 197 2696 2703 O
clinical 198 206 2704 2712 O
benefit 207 214 2713 2720 O
per 215 218 2721 2724 O
institutional 219 232 2725 2738 O
standard 233 241 2739 2747 O
of 242 244 2748 2750 O
care 245 249 2751 2755 O
. 249 250 2755 2756 O
( 251 252 2757 2758 O
various 252 259 2758 2765 O
solid 260 265 2766 2771 B-cancer
tumors 266 272 2772 2778 I-cancer
cohort 273 279 2779 2785 O
: 279 280 2785 2786 O
head 281 285 2787 2791 O
and 286 289 2792 2795 O
neck 290 294 2796 2800 O
squamous 295 303 2801 2809 O
cell 304 308 2810 2814 O
carcinoma 309 318 2815 2824 O
groups 319 325 2825 2831 O
only 326 330 2832 2836 O
) 330 331 2836 2837 O

Patients 0 8 2838 2846 O
must 9 13 2847 2851 O
have 14 18 2852 2856 O
histologically 19 33 2857 2871 O
or 34 36 2872 2874 O
cytologically 37 50 2875 2888 O
confirmed 51 60 2889 2898 O
mesothelioma 61 73 2899 2911 B-cancer
that 74 78 2912 2916 O
is 79 81 2917 2919 O
locally 82 89 2920 2927 O
advanced 90 98 2928 2936 O
or 99 101 2937 2939 O
metastatic 102 112 2940 2950 O
with 113 117 2951 2955 O
no 118 120 2956 2958 O
available 121 130 2959 2968 O
therapy 131 138 2969 2976 B-treatment
options 139 146 2977 2984 O
that 147 151 2985 2989 O
are 152 155 2990 2993 O
known 156 161 2994 2999 O
to 162 164 3000 3002 O
provide 165 172 3003 3010 O
clinical 173 181 3011 3019 O
benefit 182 189 3020 3027 O
per 190 193 3028 3031 O
institutional 194 207 3032 3045 O
standard 208 216 3046 3054 O
of 217 219 3055 3057 O
care 220 224 3058 3062 O
. 224 225 3062 3063 O
( 226 227 3064 3065 O
various 227 234 3065 3072 O
solid 235 240 3073 3078 B-cancer
tumors 241 247 3079 3085 I-cancer
cohort 248 254 3086 3092 O
, 254 255 3092 3093 O
mesothelioma 256 268 3094 3106 O
group 269 274 3107 3112 O
only 275 279 3113 3117 O
) 279 280 3117 3118 O

Patients 0 8 3119 3127 O
must 9 13 3128 3132 O
have 14 18 3133 3137 O
histologically 19 33 3138 3152 O
or 34 36 3153 3155 O
cytologically 37 50 3156 3169 O
confirmed 51 60 3170 3179 O
small 61 66 3180 3185 B-cancer
cell 67 71 3186 3190 I-cancer
lung 72 76 3191 3195 I-cancer
carcinoma 77 86 3196 3205 I-cancer
that 87 91 3206 3210 O
is 92 94 3211 3213 O
locally 95 102 3214 3221 O
advanced 103 111 3222 3230 O
or 112 114 3231 3233 O
metastatic 115 125 3234 3244 O
with 126 130 3245 3249 O
no 131 133 3250 3252 O
available 134 143 3253 3262 O
therapy 144 151 3263 3270 B-treatment
options 152 159 3271 3278 O
that 160 164 3279 3283 O
are 165 168 3284 3287 O
known 169 174 3288 3293 O
to 175 177 3294 3296 O
provide 178 185 3297 3304 O
clinical 186 194 3305 3313 O
benefit 195 202 3314 3321 O
per 203 206 3322 3325 O
institutional 207 220 3326 3339 O
standard 221 229 3340 3348 O
of 230 232 3349 3351 O
care 233 237 3352 3356 O
. 237 238 3356 3357 O
( 239 240 3358 3359 O
various 240 247 3359 3366 O
solid 248 253 3367 3372 B-cancer
tumors 254 260 3373 3379 I-cancer
cohort 261 267 3380 3386 O
, 267 268 3386 3387 O
SCLC 269 273 3388 3392 B-cancer
group 274 279 3393 3398 O
only 280 284 3399 3403 O
) 284 285 3403 3404 O

Patients 0 8 3405 3413 O
must 9 13 3414 3418 O
have 14 18 3419 3423 O
received 19 27 3424 3432 O
prior 28 33 3433 3438 B-treatment
therapy 34 41 3439 3446 I-treatment
with 42 46 3447 3451 I-treatment
an 47 49 3452 3454 I-treatment
anti 50 54 3455 3459 I-treatment
- 54 55 3459 3460 I-treatment
PD-1 55 59 3460 3464 I-treatment
or 60 62 3465 3467 I-treatment
anti 63 67 3468 3472 I-treatment
- 67 68 3472 3473 I-treatment
PD 68 70 3473 3475 I-treatment
- 70 71 3475 3476 I-treatment
L1 71 73 3476 3478 I-treatment
antibody 74 82 3479 3487 I-treatment
, 82 83 3487 3488 O
or 84 86 3489 3491 O
previously 87 97 3492 3502 B-treatment
participated 98 110 3503 3515 I-treatment
in 111 113 3516 3518 I-treatment
Merck 114 119 3519 3524 I-treatment
MK 120 122 3525 3527 I-treatment
3475 123 127 3528 3532 I-treatment
clinical 128 136 3533 3541 I-treatment
trials 137 143 3542 3548 I-treatment

Patients 0 8 3549 3557 O
who 9 12 3558 3561 O
have 13 17 3562 3566 O
received 18 26 3567 3575 O
anti 27 31 3576 3580 B-treatment
- 31 32 3580 3581 I-treatment
PD 32 34 3581 3583 I-treatment
- 34 35 3583 3584 I-treatment
L2 35 37 3584 3586 I-treatment
, 37 38 3586 3587 O
anti 39 43 3588 3592 B-treatment
- 43 44 3592 3593 I-treatment
CD137 44 49 3593 3598 I-treatment
, 49 50 3598 3599 O
or 51 53 3600 3602 O
anti 54 58 3603 3607 B-treatment
- 58 59 3607 3608 I-treatment
Cytotoxic 59 68 3608 3617 I-treatment
T 69 70 3618 3619 I-treatment
- 70 71 3619 3620 I-treatment
lymphocyte 71 81 3620 3630 I-treatment
- 81 82 3630 3631 I-treatment
associated 82 92 3631 3641 I-treatment
antigen-4 93 102 3642 3651 I-treatment
( 103 104 3652 3653 I-treatment
CTLA-4 104 110 3653 3659 I-treatment
) 110 111 3659 3660 I-treatment
antibody 112 120 3661 3669 I-treatment
( 121 122 3670 3671 O
including 122 131 3671 3680 O
ipilimumab 132 142 3681 3691 B-treatment
or 143 145 3692 3694 O
any 146 149 3695 3698 O
other 150 155 3699 3704 O
antibody 156 164 3705 3713 O
or 165 167 3714 3716 O
drug 168 172 3717 3721 B-treatment
specifically 173 185 3722 3734 O
targeting 186 195 3735 3744 O
T 196 197 3745 3746 O
- 197 198 3746 3747 O
cell 198 202 3747 3751 O
co 203 205 3752 3754 O
- 205 206 3754 3755 O
stimulation 206 217 3755 3766 O
or 218 220 3767 3769 O
checkpoint 221 231 3770 3780 O
pathways 232 240 3781 3789 O
) 240 241 3789 3790 O
( 242 243 3791 3792 O
Various 243 250 3792 3799 O
solid 251 256 3800 3805 O
tumor 257 262 3806 3811 O
cohort 263 269 3812 3818 O
, 269 270 3818 3819 O
head 271 275 3820 3824 B-cancer
and 276 279 3825 3828 I-cancer
neck 280 284 3829 3833 I-cancer
squamous 285 293 3834 3842 I-cancer
cell 294 298 3843 3847 I-cancer
carcinoma 299 308 3848 3857 I-cancer
check 309 314 3858 3863 O
point 315 320 3864 3869 O
inhibitor 321 330 3870 3879 O
experienced 331 342 3880 3891 O
group 343 348 3892 3897 O
only 349 353 3898 3902 O
) 353 354 3902 3903 O

Patients 0 8 3904 3912 O
who 9 12 3913 3916 O
have 13 17 3917 3921 O
received 18 26 3922 3930 O
any 27 30 3931 3934 O
other 31 36 3935 3940 B-treatment
investigational 37 52 3941 3956 I-treatment
agents 53 59 3957 3963 I-treatment
within 60 66 3964 3970 O
4 67 68 3971 3972 B-upper_bound
weeks 69 74 3973 3978 I-upper_bound
of 75 77 3979 3981 O
first 78 83 3982 3987 O
dose 84 88 3988 3992 O
of 89 91 3993 3995 O
study 92 97 3996 4001 B-treatment
drug 98 102 4002 4006 I-treatment

Patients 0 8 4007 4015 O
with 9 13 4016 4020 O
metastatic 14 24 4021 4031 B-cancer
colorectal 25 35 4032 4042 I-cancer
cancer 36 42 4043 4049 I-cancer
with 43 47 4050 4054 O
no 48 50 4055 4057 O
available 51 60 4058 4067 O
therapy 61 68 4068 4075 B-treatment
options 69 76 4076 4083 O
that 77 81 4084 4088 O
are 82 85 4089 4092 O
known 86 91 4093 4098 O
to 92 94 4099 4101 O
provide 95 102 4102 4109 O
clinical 103 111 4110 4118 O
benefit 112 119 4119 4126 O
per 120 123 4127 4130 O
institutional 124 137 4131 4144 O
standard 138 146 4145 4153 O
of 147 149 4154 4156 O
care 150 154 4157 4161 O

Prior 0 5 4162 4167 B-treatment
chemotherapy 6 18 4168 4180 I-treatment
, 18 19 4180 4181 O
targeted 20 28 4182 4190 B-treatment
small 29 34 4191 4196 I-treatment
molecule 35 43 4197 4205 I-treatment
therapy 44 51 4206 4213 I-treatment
or 52 54 4214 4216 O
radiotherapy 55 67 4217 4229 B-treatment
within 68 74 4230 4236 O
2 75 76 4237 4238 B-upper_bound
weeks 77 82 4239 4244 I-upper_bound
prior 83 88 4245 4250 I-upper_bound
to 89 91 4251 4253 O
first 92 97 4254 4259 O
dose 98 102 4260 4264 O
of 103 105 4265 4267 O
study 106 111 4268 4273 B-treatment
drug 112 116 4274 4278 I-treatment

Prior 0 5 4279 4284 B-treatment
monoclonal 6 16 4285 4295 I-treatment
antibody 17 25 4296 4304 I-treatment
, 25 26 4304 4305 O
within 27 33 4306 4312 O
4 34 35 4313 4314 B-upper_bound
weeks 36 41 4315 4320 I-upper_bound
prior 42 47 4321 4326 I-upper_bound
to 48 50 4327 4329 O
first 51 56 4330 4335 O
dose 57 61 4336 4340 O
of 62 64 4341 4343 O
study 65 70 4344 4349 B-treatment
drug 71 75 4350 4354 I-treatment

Prior 0 5 4355 4360 B-treatment
therapy 6 13 4361 4368 I-treatment
with 14 18 4369 4373 I-treatment
an 19 21 4374 4376 I-treatment
anti 22 26 4377 4381 I-treatment
- 26 27 4381 4382 I-treatment
PD-1 27 31 4382 4386 I-treatment
, 31 32 4386 4387 O
anti 33 37 4388 4392 B-treatment
- 37 38 4392 4393 I-treatment
PD 38 40 4393 4395 I-treatment
- 40 41 4395 4396 I-treatment
L1 41 43 4396 4398 I-treatment
, 43 44 4398 4399 O
anti 45 49 4400 4404 B-treatment
- 49 50 4404 4405 I-treatment
PD 50 52 4405 4407 I-treatment
- 52 53 4407 4408 I-treatment
L2 53 55 4408 4410 I-treatment
, 55 56 4410 4411 O
anti 57 61 4412 4416 B-treatment
- 61 62 4416 4417 I-treatment
CD137 62 67 4417 4422 I-treatment
, 67 68 4422 4423 O
or 69 71 4424 4426 O
anti 72 76 4427 4431 B-treatment
- 76 77 4431 4432 I-treatment
Cytotoxic 77 86 4432 4441 I-treatment
T 87 88 4442 4443 I-treatment
- 88 89 4443 4444 I-treatment
lymphocyte 89 99 4444 4454 I-treatment
- 99 100 4454 4455 I-treatment
associated 100 110 4455 4465 I-treatment
antigen-4 111 120 4466 4475 I-treatment
( 121 122 4476 4477 I-treatment
CTLA-4 122 128 4477 4483 I-treatment
) 128 129 4483 4484 I-treatment
antibody 130 138 4485 4493 O

Uncontrolled 0 12 4494 4506 O
intercurrent 13 25 4507 4519 O
illness 26 33 4520 4527 O
including 34 43 4528 4537 O
, 43 44 4537 4538 O
but 45 48 4539 4542 O
not 49 52 4543 4546 O
limited 53 60 4547 4554 O
to 61 63 4555 4557 O
, 63 64 4557 4558 O
symptomatic 65 76 4559 4570 O
congestive 77 87 4571 4581 B-chronic_disease
heart 88 93 4582 4587 I-chronic_disease
failure 94 101 4588 4595 I-chronic_disease
, 101 102 4595 4596 O
hypertension 103 115 4597 4609 B-chronic_disease
, 115 116 4609 4610 O
unstable 117 125 4611 4619 B-chronic_disease
angina 126 132 4620 4626 I-chronic_disease
pectoris 133 141 4627 4635 I-chronic_disease
, 141 142 4635 4636 O
cardiac 143 150 4637 4644 B-chronic_disease
arrhythmia 151 161 4645 4655 I-chronic_disease
, 161 162 4655 4656 O
autoimmune 163 173 4657 4667 B-chronic_disease
disease 174 181 4668 4675 I-chronic_disease
or 182 184 4676 4678 O
inflammatory 185 197 4679 4691 B-chronic_disease
diseases 198 206 4692 4700 I-chronic_disease
, 206 207 4700 4701 O
or 208 210 4702 4704 O
psychiatric 211 222 4705 4716 B-chronic_disease
illness 223 230 4717 4724 I-chronic_disease
/ 230 231 4724 4725 O
social 231 237 4725 4731 O
situations 238 248 4732 4742 O
that 249 253 4743 4747 O
would 254 259 4748 4753 O
limit 260 265 4754 4759 O
compliance 266 276 4760 4770 O
with 277 281 4771 4775 O
study 282 287 4776 4781 O
requirements 288 300 4782 4794 O

